Aim: Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells and it has been proposed as a potential biomarker of different ILD. Materials & methods: A growing literature about KL-6 has been reviewed and selected to evaluate its role in the clinical management of ILD to predict disease diagnosis, activity, prognosis and treatment response. Results: KL-6 concentrations have been evaluated in fibrotic and granulomatous lung diseases and it was demonstrated to be a biomarker of disease severity useful for clinical follow-up of ILD patients. KL-6 levels differentiated between fibrotic ILD, such as idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis, and nonfibrotic lung disorders, including sarcoidosis and pulmonary alveolar proteinosis. Conclusion: KL-6 is predictive biomarker useful in the clinical management of ILD patients, in particular in patients with severe fibrotic lung disorders.
Aim: Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells and it has been proposed as a potential biomarker of different ILD. Materials & methods: A growing literature about KL-6 has been reviewed and selected to evaluate its role in the clinical management of ILD to predict disease diagnosis, activity, prognosis and treatment response. Results:KL-6 concentrations have been evaluated in fibrotic and granulomatous lung diseases and it was demonstrated to be a biomarker of disease severity useful for clinical follow-up of ILDpatients. KL-6 levels differentiated between fibrotic ILD, such as idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis, and nonfibrotic lung disorders, including sarcoidosis and pulmonary alveolar proteinosis. Conclusion:KL-6 is predictive biomarker useful in the clinical management of ILDpatients, in particular in patients with severe fibrotic lung disorders.
Authors: Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Maria Pieroni; Rosa Metella Refini; Piersante Sestini; Elena Bargagli Journal: Cancers (Basel) Date: 2021-02-09 Impact factor: 6.639
Authors: Miriana d'Alessandro; Laura Bergantini; Dalila Cavallaro; Sara Gangi; Paolo Cameli; Edoardo Conticini; Bruno Frediani; Francesco Dotta; Elena Bargagli Journal: Int J Environ Res Public Health Date: 2022-02-15 Impact factor: 3.390
Authors: Miriana d'Alessandro; Edoardo Conticini; Laura Bergantini; Paolo Cameli; Luca Cantarini; Bruno Frediani; Elena Bargagli Journal: Life (Basel) Date: 2022-02-20
Authors: Miriana d'Alessandro; Laura Bergantini; Paolo Cameli; Giuseppe Curatola; Lorenzo Remediani; Piersante Sestini; Elena Bargagli Journal: J Med Virol Date: 2020-10-10 Impact factor: 20.693